Seqens is unveiling its main innovation and development centre in the presence of Ms. Agnès Pannier-Runacher, Secretary of State to the Minister…
Read moreEmergence of a new global CDMO Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI…
Read moreQ: Frederic Desdouits, Managing Director at Seqens CDMO, tells us more about the strategy behind the group’s recent consolidation and…
Read moreThe brand new office in Shanghai was inaugurated the 8th of July in presence of Pierre Luzeau, Seqens’CEO. Seqens Shanghai office…
Read moreOn July 3rd, 2019, the Canadian manufacturing site of the Seqens group located in Saint-Jean-sur-Richelieu is celebrating its 30th anniversary!…
Read moreIn 2018, the FDA reported that some generic versions of the angiotensin II…
Read moreABACUS is a 3-year project, funded by the Bio-Based Industries Joint Undertaking under the European Union’s Horizon 2020 research and innovation program,…
Read moreThis eBook takes a detailed look at the issues that affect the pharmaceutical manufacturing industry. Topics range from general industry outlook trends to…
Read moreSo you have a breakthrough molecule you need developed, investors breathing down your neck and it’s urgent you see this drug through to…
Read moreAs an integrated global leader in pharmaceutical synthesis and specialty ingredients, Seqens performs many challenging chemistry projects. We develop the active pharmaceutical…
Read moreSince May 2019, all biological actives produced by Seqens Cosmetics have been traced on the blockchain (ACT4s.com), which makes it possible…
Read more